b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="Publisher" Owner="NLM">\n        <PMID Version="1">31018685</PMID>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>06</Month>\n            <Day>17</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1724-6016</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>Apr</Month>\n                        <Day>25</Day>\n                    </PubDate>\n                </JournalIssue>\n                <Title>European journal of ophthalmology</Title>\n                <ISOAbbreviation>Eur J Ophthalmol</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>XEN implant in primary and secondary open-angle glaucoma: A 12-month retrospective study.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>1120672119845226</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1177/1120672119845226</ELocationID>\n            <Abstract>\n                <AbstractText Label="PURPOSE" NlmCategory="UNASSIGNED">The aim of this study was to compare the efficacy and safety of the XEN45 gel stent implant in patients with primary open-angle glaucoma or secondary open-angle glaucoma.</AbstractText>\n                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="UNASSIGNED">This is a retrospective, single-center, and comparative study conducted in consecutive primary open-angle glaucoma or secondary open-angle glaucoma patients, who underwent a XEN45 implant, alone or in combination with phacoemulsification. The primary end point was the intraocular pressure at the end of the follow-up period. Complete success was defined as an intraocular pressure reduction of \xe2\xa9\xbe20% from baseline to month 12 without antiglaucoma treatment.</AbstractText>\n                <AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Of the 69 patients (74 eyes) who were screened, 68 patients (73 eyes) were included in this study. In the overall study population, XEN gel stent significantly reduced intraocular pressure from 22.3 (21.0-23.5) mmHg at baseline to 15.3 (14.3-16.3) mmHg, <i>p</i>\xe2\x80\x89&lt;\xe2\x80\x890.0001. As compared to baseline, mean intraocular pressure reduction was -7.3 (-9.7 to -5.0) and -6.6 (-8.4 to -4.8) mmHg in the primary open-angle glaucoma and secondary open-angle glaucoma groups, respectively, <i>p</i>\xe2\x80\x89=\xe2\x80\x890.6357. At month 12, 53 (72.6%) eyes were classified as success. The mean number of antiglaucoma medications was significantly reduced in both groups (<i>p</i>\xe2\x80\x89&lt;\xe2\x80\x890.0001, each). Complications included anterior chamber flattening (one eye), XEN implant extrusion (four eyes), one of whom had an endophthalmitis that required vitrectomy, and one eye underwent a trabeculectomy due to inadequate intraocular pressure control.</AbstractText>\n                <AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">XEN gel stent, either alone or in combination with phacoemulsification, provided a significant reduction in both intraocular pressure and medical antiglaucoma treatment, but with some safety concerns, in a cohort of patients with open-angle glaucoma (primary or secondary).</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Ib\xc3\xa1\xc3\xb1ez-Mu\xc3\xb1oz</LastName>\n                    <ForeName>Ana</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Ophthalmology Department, San Pedro Hospital, Logro\xc3\xb1o, Spain.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Soto-Biforcos</LastName>\n                    <ForeName>V\xc3\xadctor Santiago</ForeName>\n                    <Initials>VS</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Ophthalmology Department, Mont-de-Marsan Hospital, Mont-de-Marsan, France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Rodr\xc3\xadguez-Vicente</LastName>\n                    <ForeName>Leticia</ForeName>\n                    <Initials>L</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Ophthalmology Department, San Pedro Hospital, Logro\xc3\xb1o, Spain.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Ortega-Renedo</LastName>\n                    <ForeName>Irune</ForeName>\n                    <Initials>I</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Ophthalmology Department, San Pedro Hospital, Logro\xc3\xb1o, Spain.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Chac\xc3\xb3n-Gonz\xc3\xa1lez</LastName>\n                    <ForeName>Mar\xc3\xada</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Ophthalmology Department, San Pedro Hospital, Logro\xc3\xb1o, Spain.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>R\xc3\xbaa-Galisteo</LastName>\n                    <ForeName>Oscar</ForeName>\n                    <Initials>O</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Ophthalmology Department, San Pedro Hospital, Logro\xc3\xb1o, Spain.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Arrieta-Los Santos</LastName>\n                    <ForeName>Alexandra</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Ophthalmology Department, San Pedro Hospital, Logro\xc3\xb1o, Spain.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Lizuain-Abad\xc3\xada</LastName>\n                    <ForeName>Mar\xc3\xada Ester</ForeName>\n                    <Initials>ME</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Ophthalmology Department, San Pedro Hospital, Logro\xc3\xb1o, Spain.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Del R\xc3\xado Mayor</LastName>\n                    <ForeName>Jos\xc3\xa9 Luis</ForeName>\n                    <Initials>JL</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Ophthalmology Department, San Pedro Hospital, Logro\xc3\xb1o, Spain.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2019</Year>\n                <Month>04</Month>\n                <Day>25</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>United States</Country>\n            <MedlineTA>Eur J Ophthalmol</MedlineTA>\n            <NlmUniqueID>9110772</NlmUniqueID>\n            <ISSNLinking>1120-6721</ISSNLinking>\n        </MedlineJournalInfo>\n        <CitationSubset>IM</CitationSubset>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="N">Primary open-angle glaucoma</Keyword>\n            <Keyword MajorTopicYN="N">XEN gel stent</Keyword>\n            <Keyword MajorTopicYN="N">glaucoma stage</Keyword>\n            <Keyword MajorTopicYN="N">intraocular pressure</Keyword>\n            <Keyword MajorTopicYN="N">minimally invasive glaucoma surgery</Keyword>\n            <Keyword MajorTopicYN="N">secondary open-angle glaucoma</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>4</Month>\n                <Day>26</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>4</Month>\n                <Day>26</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>4</Month>\n                <Day>26</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>aheadofprint</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">31018685</ArticleId>\n            <ArticleId IdType="doi">10.1177/1120672119845226</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'